Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 2
1967 5
1968 1
1969 3
1970 1
1971 4
1972 1
1973 4
1974 3
1975 6
1976 3
1977 6
1978 5
1979 8
1980 10
1981 6
1982 12
1983 7
1984 13
1985 8
1986 10
1987 9
1988 14
1989 31
1990 25
1991 18
1992 12
1993 21
1994 19
1995 27
1996 24
1997 24
1998 22
1999 41
2000 50
2001 48
2002 40
2003 33
2004 38
2005 34
2006 42
2007 37
2008 25
2009 19
2010 19
2011 11
2012 13
2013 11
2014 9
2015 9
2016 9
2017 3
2018 4
2019 2
2020 8
2021 2
2022 8
2023 7
2024 9
2025 4
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

857 results

Results by year

Filters applied: . Clear all
Page 1
Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials.
Donnez J, Taylor HS, Stewart EA, Bradley L, Marsh E, Archer D, Al-Hendy A, Petraglia F, Watts N, Gotteland JP, Bestel E, Terrill P, Loumaye E, Humberstone A, Garner E. Donnez J, et al. Lancet. 2022 Sep 17;400(10356):896-907. doi: 10.1016/S0140-6736(22)01475-1. Lancet. 2022. PMID: 36116480 Clinical Trial.
Two phase 3 trials were conducted to confirm the efficacy and safety of linzagolix at full-suppression (200 mg) and partial-suppression (100 mg) doses with or without hormonal add-back therapy (1 mg oestradiol and 0.5 mg norethisterone acetate) compared with placebo …
Two phase 3 trials were conducted to confirm the efficacy and safety of linzagolix at full-suppression (200 mg) and partial-suppression (100 …
Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3).
Donnez J, Becker C, Taylor H, Carmona Herrera F, Donnez O, Horne A, Paszkowski M, Petraglia F, Renner SP, Patel A, Boolell M, Bestel E, Dolmans MM. Donnez J, et al. Hum Reprod. 2024 Jun 3;39(6):1208-1221. doi: 10.1093/humrep/deae076. Hum Reprod. 2024. PMID: 38648863 Free PMC article. Clinical Trial.
STUDY QUESTION: Does linzagolix administered orally once daily for up to 3 months at a dose of 75 mg alone or 200 mg in combination with add-back therapy (ABT) (1.0 mg estradiol; 0.5 mg norethindrone acetate, also known as norethisterone acetate [NETA]) demon …
STUDY QUESTION: Does linzagolix administered orally once daily for up to 3 months at a dose of 75 mg alone or 200 mg in combination with add …
Efficacy and safety of relugolix combination therapy in women with uterine fibroids and adenomyosis: subgroup analysis of LIBERTY 1 and LIBERTY 2.
Catherino WH, Al-Hendy A, Zaim S, Bouzegaou N, Venturella R, Stewart EA, Wu R, Vannuccini S, Perry JS, Rakov VG, Munro MG. Catherino WH, et al. Fertil Steril. 2025 Sep;124(3):523-533. doi: 10.1016/j.fertnstert.2025.04.037. Epub 2025 May 2. Fertil Steril. 2025. PMID: 40320117 Free article. Clinical Trial.
INTERVENTION: Once-daily relugolix combination therapy (40 mg relugolix, 1 mg estradiol, and 0.5 mg of norethindrone acetate) or placebo for 24 weeks, or delayed relugolix combination therapy (40 mg of relugolix monotherapy for 12 weeks, followed by relugolix combin …
INTERVENTION: Once-daily relugolix combination therapy (40 mg relugolix, 1 mg estradiol, and 0.5 mg of norethindrone acetate) …
Linzagolix with and without hormonal add-back therapy for symptomatic uterine fibroids: PRIMROSE 1 & 2 long-term extension and withdrawal study.
Donnez J, Petraglia F, Taylor H, Becker CM, Becker S, Herrera FC, Bestel E, Hori S, Dolmans MM. Donnez J, et al. Fertil Steril. 2025 Oct;124(4):737-748. doi: 10.1016/j.fertnstert.2025.06.016. Epub 2025 Jun 19. Fertil Steril. 2025. PMID: 40543832 Free article. Clinical Trial.
OBJECTIVE: To evaluate whether oral linzagolix administered once daily for up to 52 weeks (extension study) at a dose of 100 mg or 200 mg with or without hormonal add-back therapy (ABT) (1.0 mg estradiol; 0.5 mg norethisterone acetate) can maintain the efficacy and …
OBJECTIVE: To evaluate whether oral linzagolix administered once daily for up to 52 weeks (extension study) at a dose of 100 mg or 200 mg wi …
Impact of relugolix combination therapy on functioning and quality of life in women with endometriosis-associated pain.
As-Sanie S, Abrao MS, Reznichenko G, Wilk K, Zhong Y, Perry J, Hunsche E, Soulban G, Becker CM. As-Sanie S, et al. Fertil Steril. 2024 Oct;122(4):687-695. doi: 10.1016/j.fertnstert.2024.06.009. Epub 2024 Jun 19. Fertil Steril. 2024. PMID: 38906210 Free article. Clinical Trial.
OBJECTIVE: To evaluate the effect of relugolix combination therapy (relugolix CT; 40 mg relugolix, 1 mg estradiol, and 0.5 mg norethisterone acetate) for up to 2 years in the SPIRIT long-term extension study on functioning and health-related quality of life (QoL), u …
OBJECTIVE: To evaluate the effect of relugolix combination therapy (relugolix CT; 40 mg relugolix, 1 mg estradiol, and 0.5 mg nore …
Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial.
Miller CE, Kim JH, Kroll R, Simon JA, Soliman AM, Thomas JW, Xu Y, Ng J, Snabes MC. Miller CE, et al. Am J Obstet Gynecol. 2024 Dec;231(6):630.e1-630.e13. doi: 10.1016/j.ajog.2024.06.040. Epub 2024 Jun 30. Am J Obstet Gynecol. 2024. PMID: 38955323 Free article. Clinical Trial.
OBJECTIVE: To evaluate efficacy, tolerability, and bone density outcomes of elagolix 200 mg twice daily with 1 mg estradiol/0.5 mg norethindrone acetate (add-back) therapy once daily compared with placebo in premenopausal women with moderate-to-severe endometriosis- …
OBJECTIVE: To evaluate efficacy, tolerability, and bone density outcomes of elagolix 200 mg twice daily with 1 mg estradiol/0.5 mg …
Norethindrone acetate and estradiol-induced endometrial hyperplasia.
Kurman RJ, Félix JC, Archer DF, Nanavati N, Arce J, Moyer DL. Kurman RJ, et al. Obstet Gynecol. 2000 Sep;96(3):373-9. doi: 10.1016/s0029-7844(00)00944-3. Obstet Gynecol. 2000. PMID: 10960628 Free article. Clinical Trial.
OBJECTIVE: To identify the lowest effective continuous dose of norethindrone acetate that significantly reduces 12-month incidence of endometrial hyperplasia associated with unopposed 17beta-estradiol (E2), 1 mg. ...RESULTS: Continuous-combined E2-norethindrone …
OBJECTIVE: To identify the lowest effective continuous dose of norethindrone acetate that significantly reduces 12-month incidence of …
Menopausal therapy and endometrial pathology.
Craft I, Swinhoe J, Mugglestone CJ. Craft I, et al. Br Med J. 1978 Aug 5;2(6134):429-30. doi: 10.1136/bmj.2.6134.429-c. Br Med J. 1978. PMID: 687955 Free PMC article. Clinical Trial.
Small treatment groups received either 1) cyclical estradiol valerate 2 mg plus norgestrel .5 mg for 21 of 28 days; 2) continuous estradiol valerate 2 mg plus norgestrel .5 mg daily; 3) continuous estradiol valerate 1 mg twice daily plus levonorgestrel .25 mg …
Small treatment groups received either 1) cyclical estradiol valerate 2 mg plus norgestrel .5 mg for 21 of 28 days; 2) continuous …
A Randomized Open-Label Study of Relugolix Alone or Relugolix Combination Therapy in Premenopausal Women.
Lukes A, Migoya E, Johnson B, Lee TY, Li Y, Arjona Ferreira JC. Lukes A, et al. Clin Pharmacokinet. 2023 Aug;62(8):1169-1182. doi: 10.1007/s40262-023-01269-9. Epub 2023 Jun 26. Clin Pharmacokinet. 2023. PMID: 37365436 Free PMC article. Clinical Trial.
This study assessed whether the addition of estradiol (E2) 1 mg and norethindrone acetate (NETA) 0.5 mg to relugolix 40 mg (relugolix combination therapy) provides systemic E2 concentrations in the 20-50 pg/mL range to minimize these undesirable effects. ...Study as …
This study assessed whether the addition of estradiol (E2) 1 mg and norethindrone acetate (NETA) 0.5 mg to relugolix 40 mg (re …
Linzagolix rapidly reduces heavy menstrual bleeding in women with uterine fibroids: an analysis of the PRIMROSE 1 and 2 trials.
Donnez J, Becker CM, Mangler M, Paszkowski M, Paszkowski T, St-Pierre J, Ionescu-Ittu R, Boolell M, Bestel E, Hori S, Petraglia F. Donnez J, et al. Fertil Steril. 2025 Jun;123(6):1093-1100. doi: 10.1016/j.fertnstert.2024.12.031. Epub 2025 Jan 3. Fertil Steril. 2025. PMID: 39755138 Free article. Clinical Trial.
Eligible participants were randomized equally across four treatment arms (linzagolix 100 mg and 200 mg, with and without concomitant hormonal add-back therapy [ABT] consisting of 1-mg estradiol and 0.5-mg norethisterone acetate) and one placebo arm. The cumulative i …
Eligible participants were randomized equally across four treatment arms (linzagolix 100 mg and 200 mg, with and without concomitant hormona …
857 results